Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables and specialty-testing services to the worldwide pharmaceuticals, biotherapeutics, nutraceuticals, cosmeceuticals, agrochemical, food & beverage, cannabis and other industries, has partnered with Bioscreen Instruments PVT LTD through an exclusive instrument and consumables distribution agreement for India. Bioscreen is a leading supplier of highly advanced lab automation, instruments and consumables for India’s growing life sciences industry. According to the announcement, the Indian pharmaceutical industry is 13th largest by value and third largest by volume in the world, is the largest global supplier of generic medicines, and is ranked third in the world in terms of dollar value of drugs and medicines exports. The company noted that the agreement provides an opportunity to expand into the Indian market.
“Our team has been focusing the majority of our efforts on the launch of our revolutionary UltraShear(TM) nanoemulsions processing platform, which we expect to be pivotal to ramping revenue in the fourth quarter of 2023, and beyond,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “However, our commitment to supporting the PCT platform, which has for years been the backbone of our company, remains unwavering. We are honored and humbled to have partnered with such a renowned and leading life sciences distribution company in India. With access to one of the world’s largest and fastest-growing life sciences markets, and with established access to many thousands of companies making up this market, we believe PCT instrument and consumables sales in 2024 will be a strong contributor to PBIO’s growth trajectory as well.”
To view the full press release, visit https://ibn.fm/K8fsp
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. The company’s first patented enabling technology platform, Pressure Cycling Technology (“PCT”), is used to control biomolecular interactions such as cell lysis and biomolecule extraction safely and reproducibly, for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics and counterbioterrorism applications. The company’s acquisition of the BaroFold(TM) patented technology platform in 2017 allowed it to offer important new biopharma contract services and GMP manufacturing equipment to this enormous market sector. Most recently, PBIO developed the commercially scalable and high-efficiency pressure-based Ultra Shear Technology(TM) platform, which allows the company to produce stable and precisely controlled nanoemulsions of otherwise immiscible oil and water components. It also allows for the preparation of higher-quality, homogenized, extended shelf-life or room-temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as the leader in high-pressure platform technologies, providing unique and effective solutions to diverse, major (and growing) global market sectors. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
